Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2802)	2/4/2001 6:00:22 PM
From: thebeach	Respond to of 52153

For anyone following PBP-TO,Procyon Biopharma,here's a paste from another thread: As with Vasogen, in this earnings-are-everything environment, the accountants are not helpful to any of the junior biotechs, including Procyon Biopharma (PBP-TSE, $1.35, 514-685-9283, www.procyonbiopharma.com)." "Despite the important progress being demonstrated, and the fact that the company had already received $5 million of the recent $20.4 million financing, total assets at June 30, 2000, were only $7.46 million." "Adding to the average investor's confusion is the sad appearance of the shareholders' equity account, sporting a deficit of $11 million. Why would anyone want to buy or hold this stock? Is it really not possible to come up with a financial statment that could be more helpful?" "Despite the fact that the financial statements of both these companies are virtually useless in determining their investment merits - and in fact do a disservice by misleading the average investor - both equities have exceptional investment merit around current prices." - end of article «